Sanara MedTech Inc. is listed today as Sanara MedTech Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2023 | $3 M | Private placement after listing | $2 to $10 million | equity | SEC | |
| Jul 2022 | $16 M | Private placement after listing | $10 to $50 million | equity | SEC | |
| Apr 2022 | $15 M | Private placement after listing | $10 to $50 million | equity | SEC | |
| Jan 2021 | $1 M | Private placement after listing | Under $2 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Sanara MedTech Inc., its revenue in fiscal 2025 came from these product and service lines: Soft Tissue Repair Products $91.35 million (89%), Bone Fusion Products $11.77 million (11%).
Annual report (SEC XBRL) · Dec 2025
Sanara MedTech Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2023).
SEC Form D · Aug 2023
The industry group it chose in its notices: Other Health Care.
SEC Form D · Aug 2023
Products and services#
No products or services of Sanara MedTech Inc. are on record.
Investors#
6 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Catalyst Rochal, LLC | Other | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| CGI Cellerate RX, LLC | Other | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Darren Stine | Person | not stated | not stated | Held Series D preferred stock (Form 3, 2014) | SEC Form 3 |
| James W. Stuckert | Person | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| John Christopher Siedhoff | Person | not stated | not stated | Held Series D preferred stock, director (Form 3, 2017) | SEC Form 3 |
| S. Oden Howell Jr. | Person | not stated | not stated | Held Series C preferred stock, 10% owner, director (Form 3, 2015) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Sanara MedTech Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$15 M4.68%
- Glazer Capital, LLC$12 M3.81%
- Vanguard Capital Management LLC$7 M2.12%
- Qube Research & Technologies Ltd$6 M1.92%
- Transmarket Holdings LP$5 M1.62%
- Abc Arbitrage SA$5 M1.53%
- Toronto Dominion Bank$4 M1.31%
- Renaissance Technologies LLC$4 M1.24%
- Gardner Lewis Asset Management L P$4 M1.22%
- Geode Capital Management, LLC$4 M1.15%
- Alberta Investment Management Corp$4 M1.12%
- Polar Asset Management Partners Inc.$3 M0.90%
- State Street Corp$2 M0.74%
- Sagefield Capital LP$2 M0.72%
- ExodusPoint Capital Management, LP$2 M0.58%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Michael D. McNeil | Chief Financial Officer | Aug 2023 |
| Zachary B. Fleming | Chief Executive Officer | Aug 2023 |
| Christopher A. Morrison | President, Telehealth Services | Jul 2022 |
| Rebecca E. McMahon | President, Research and Development | Jul 2022 |
| Shawn M. Bowman | President, Strategic Partnerships | Jul 2022 |
| J. Michael Carmena | Vice Chairman and Principal Executive Officer | Jan 2021 |
| Michael Michael McNeil | Chief Financial Officer | Jan 2021 |
| Shawn Michael Bowman | Co-Chief Operating Officer and President, Wound Care | Jan 2021 |
| Zachary Michael Fleming | Co-Chief Operating Officer and President, Surgical | Jan 2021 |
| Ann Beal Salamone | Director | Aug 2023 |
| Eric D. Major | Director | Aug 2023 |
| Eric D. Tanzberger | Director | Aug 2023 |
| James W. Stuckert | Director | Aug 2023 |
| Robert A. DeSutter | Director | Aug 2023 |
| Ronald T. Nixon | Executive Chairman | Aug 2023 |
| Roszell A. Mack III | Director | Aug 2023 |
| Sara N. Ortwein | Director | Aug 2023 |
| Kenneth E. Thorpe | Director | Jul 2022 |
| Ann Michael Salamone | Director | Jan 2021 |
| J. Michael Carmena | Vice Chairman and Principal Executive Officer | Jan 2021 |
| James Michael Stuckert | Director | Jan 2021 |
| Kenneth Michael Thorpe | Director | Jan 2021 |
| Robert Michael DeSutter | Director | Jan 2021 |
| Ronald Michael Nixon | Director | Jan 2021 |
| Sara Michael Ortwein | Director | Jan 2021 |
Went public since 2012. Its SEC number is that of a company listed on a stock exchange.